Capsulution NanoScience AG Renowned Pharma Expert has joined Scientific Advisory Board
Berlin (February 18, 2003) - Internationally renowned pharma expert Prof. Dr. Clive G. Wilson has recently become a member of the scientific advisory board of the Berlin-based technology company Capsulution NanoScience AG.
Prof. Dr. Clive G. Wilson is an expert in pharmaceutics and president of the Controlled Release Society, UK. After having undertaken a number of lectureships in the UK, he is currently Professor of Pharmaceutics at the Strathclyde Institute for Biomedical Sciences, Glasgow, UK, Adjunct Professor of Industrial Pharmacy & Pharmaceutics at the University of Cincinnati, Ohio, USA and Scientific Director at "Bio-Images Research" Glasgow, UK. The research for which he is best known focuses on the study of the behaviour of drug dosage formulations. Among his main research achievements are the Pfizer Award for Research in the Pharmaceutical Sciences, 1985 as well as the Cyanamid Award in 1993 for research into the relationship between drug release and the absorption into the human gastrointestinal tract.
Dr. Karsten Cremer, CEO of Capsulution commenting on Prof. Wilson's appointment, said: "With the appointment of Prof. Wilson to our scientific advisory board Capsulution is strengthening its international position as one of the most innovative companies in the field of drug delivery systems. Prof. Wilson is a renowned pharmaceutical expert whose extensive knowledge and experience will add prominently to the development of our products."
About Capsulution NanoScience AG:
Capsulution NanoScience develops innovative drug-delivery systems for the simple, efficient and safe delivery of pharmaceutically active compounds. The company applies the so-called
LBL-Technology® to build-up the walls of nano- and micro-capsules in a layer-by-layer fashion. This technology is a high-tech tool for the creation of nano- and micro-sized capsules. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules (100 nm to 100 µm) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. The capsules are already applied for the delivery of drugs, in cosmetic products, in diagnostics, and for crop protection. Today, the Berlin-based company has 17 employees. In 2001 Capsulution successfully completed its first round of financing raising around three million Euro. Investors in the company include venture capital companies like Berlin Seed Capital Fund (BSCF), and tbg, the Technologiebeteiligungsgesellschaft (Technology Equity Company) of the Deutsche Ausgleichsbank. Capsulution has already entered into several co-operation agreements with industrial corporations, including one with Bayer AG in December 2001.
Contact:
Capsulution NanoScience AG
Alexander Herrmann (CFO)
Volmerstr. 7b
D- 12489 Berlin, Germany
Tel.: +49-(0)30-63923627
Fax.: +49-(0)30-63923601
Web: www.capsulution.com
eMail: alexander.herrmann@capsulution.com
© BIOCOMMUNICATIONS.net GmbH, Brunnenstr. 128, D-13355 Berlin, Germany - Reprint free of charge, please supply copy
